Skip to main
EXEL

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 19%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc. demonstrates a positive outlook driven by the promising results from the Phase 3 STELLAR-303 trial, wherein zanzalintinib combined with atezolizumab showed statistically significant improvements in overall survival for metastatic colorectal cancer. The strategic collaboration with Natera to utilize the Signatera test for detecting minimal residual disease in the upcoming STELLAR-316 trial further enhances the potential of Exelixis's pipeline, underscoring the company's commitment to innovative cancer treatments. A discounted cash flow analysis estimates Exelixis's firm value at approximately $13.6 billion, reflecting confidence in the future commercial prospects of its drug candidates, particularly zanzalintinib.

Bears say

Exelixis Inc faces significant commercial risks primarily associated with its key product, Cabometyx (cabozantinib), which could impact its revenue generation capabilities. Furthermore, the ongoing clinical programs, particularly those involving zanzalintinib, must yield favorable data; otherwise, investment in these initiatives may not materialize into profitable outcomes. The presence of generic erosion for existing franchises, especially cabozantinib, coupled with potential long-term dilution risks, presents additional challenges that could hinder the company’s financial stability and growth prospects.

Exelixis (EXEL) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 19% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 16 analysts, Exelixis (EXEL) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.